'%20fill='%23FFFFFF'%20fill-rule='nonzero'%3e%3cg%20id='编组-4'%20transform='translate(22,%20229)'%3e%3cg%20id='icon_house'%20transform='translate(0,%204)'%3e%3cpath%20d='M8.99922372,9.15822616%20C8.99922372,9.48991119%208.75646074,9.76395043%208.43946445,9.81103455%20L8.34230709,9.81818182%20L0.656916627,9.81818182%20C0.293743207,9.81818182%200,9.52307969%200,9.15822616%20L0,4.02881469%20L0.001,4.011%20L0.001,4%20L0.002,3.984%20L0.002,3.982%20L0.00347755999,3.96620208%20L0,4.02881469%20C0,3.98423336%200.00438567647,3.94069345%200.0127478087,3.89860606%20C0.0151442154,3.88995401%200.0171448236,3.88091103%200.0193356911,3.8719086%20C0.0412453456,3.77875456%200.0832633426,3.69369516%200.140179582,3.62097729%20C0.145625488,3.61558799%200.150447315,3.6096756%200.155385716,3.60383308%20C0.180870128,3.57190551%200.210149204,3.54297617%200.241899627,3.51697285%20L4.06834342,0.161635482%20C4.14923124,0.0938412587%204.2250197,0.0533118663%204.30481399,0.0283483131%20C4.32141221,0.0232136531%204.33824457,0.0186711348%204.35518781,0.0148145509%20L4.36515101,0.01258835%20C4.39297273,0.00674989891%204.42109435,0.0027083944%204.44930269,0.000496353642%20L4.54517544,4.11920498e-13%20C4.57981979,0.0027083944%204.60790374,0.00674989891%204.63571251,0.0126335653%20L4.64597235,0.0147758337%20C4.66255859,0.0186711348%204.67936849,0.0232136531%204.69602544,0.0284449874%20C4.77614096,0.0533118663%204.85186025,0.0938412587%204.91866191,0.149611412%20L4.93221549,0.161635482%20L8.76388424,3.52241674%20C8.81862726,3.56844512%208.86577648,3.62327796%208.90318768,3.68476114%20L8.92145822,3.71659404%20L8.93512695,3.74380637%20L8.94765176,3.77177403%20C8.95369408,3.78560926%208.95917615,3.79995443%208.96414564,3.81444558%20C8.96853228,3.82810692%208.97271142,3.8418143%208.97645117,3.85570427%20C8.98193012,3.87455258%208.98622933,3.89369541%208.98967438,3.91297182%20C8.99151421,3.92631309%208.99348474,3.93996745%208.99503372,3.95375128%20C8.99788567,3.97306495%208.99924865,3.99211237%208.99979182,4.01118722%20L8.99922372,9.15822616%20Z%20M4.5,1.53448757%20L1.313,4.32948757%20L1.313,8.498%20L7.685,8.498%20L7.685,4.32748757%20L4.5,1.53448757%20Z'%20id='形状结合'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
维立志博矢志成为一家综合性生物技术公司，已经建立从早期筛选及发现、临床前研究、临床开发、CMC到中试生产的整个药物开发过程中的所有基本功能。
早期研发
临床开发
CMC及生产
早期研发
成功建立涵盖抗体发现及工程、体内及体外疗效评估以及成药性评估的综合研发能力，拥有高效的药物开发流程
3年内
实现从靶点选择至提交IND
* 根据弗若斯特沙利文的资料，显著快于行业5~6年的平均水平
'%20fill='%23A98C60'%20fill-rule='nonzero'%3e%3cg%20id='菜单-抗体'%20transform='translate(175,%201635)'%3e%3cpath%20d='M21.9836632,14.4213187%20L15.1774475,1.80795213%20C14.2684371,0.133360258%2012.194757,-0.49106383%2010.5301316,0.417189389%20C8.87118758,1.32544261%208.25192421,3.4201016%209.14957203,5.10037005%20L15.6319527,17.1120189%20L15.6319527,36.5486378%20C15.6319527,38.4559695%2017.1659079,40%2019.0577858,40%20C20.9496638,40%2022.4836189,38.4502929%2022.4836189,36.5486378%20L22.4836189,16.5840967%20C22.4836189,16.2832378%2022.4438497,15.9994087%2022.3813553,15.7155796%20C22.3359047,15.2671295%2022.1995532,14.8300327%2021.9836632,14.4213187%20Z%20M6.43958465,6.04835935%20C5.53625552,4.37376748%203.45689414,3.74934339%201.79226877,4.65759661%20C0.133324711,5.57152641%20-0.485938652,7.66050881%200.411709159,9.34077727%20L7.21792484,21.9598204%20C8.12125396,23.6344123%2010.2006153,24.2588364%2011.8652407,23.3505832%20C13.5241848,22.44233%2014.1434481,20.347671%2013.2458003,18.6674025%20L6.43958465,6.04835935%20Z%20M38.4707516,0.825903338%20C36.8118075,-0.0880264642%2034.7267648,0.536397624%2033.8234357,2.21666608%20L27.01722,14.8357092%20C26.8524619,15.1422447%2026.7331542,15.4714865%2026.6649785,15.8120815%20C26.602484,16.0675277%2026.5740774,16.3343271%2026.5740774,16.5897733%20L26.5740774,36.5486378%20C26.5740774,38.4559695%2028.1080325,40%2029.9999105,40%20C31.8917885,40%2033.4257436,38.4502929%2033.4257436,36.5486378%20L33.4257436,17.395848%20L39.8456298,5.50340742%20C40.7603216,3.83449213%2040.1410582,1.73415656%2038.4707516,0.825903338%20Z%20M47.2029331,5.06063397%20C45.5439891,4.14670417%2043.4589464,4.77112826%2042.5556172,6.45139671%20L35.7494015,19.0647633%20C34.8403911,20.7393552%2035.4596545,22.8340142%2037.1299612,23.747944%20C38.7889052,24.6561972%2040.8739479,24.0374497%2041.777277,22.3571812%20L48.5834927,9.73813805%20C49.4868218,8.06922276%2048.8732398,5.97456377%2047.2029331,5.06063397%20L47.2029331,5.06063397%20Z'%20id='icon_01'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
抗体发现及工程
整合并利用多种发现平台及技术，主要包括全人源噬菌体库、杂交瘤技术、羊驼免疫库
'%20fill='%23A98C60'%20fill-rule='nonzero'%3e%3cg%20id='icon_02备份'%20transform='translate(21,%201400)'%3e%3cpath%20d='M13.9975996,32%20C13.8485545,31.9988046%2013.7008207,31.9715975%2013.5608506,31.919567%20C5.45586049,29.1902704%20-0.0113157146,21.4882866%201.75869049e-05,12.8155222%20L1.75869049e-05,5.15733012%20C0.0032571782,4.52573597%200.413849954,3.97101215%201.01031718,3.79240728%20L13.6136444,0.065680504%20C13.7363489,0.0226431342%2013.8653898,0.0012111061%2013.9951999,0.002309085%20C14.0511523,-0.000769695%2014.1072278,-0.000769695%2014.1631802,0.002309085%20C14.2448795,0.0096908996%2014.3254309,0.0268720349%2014.4031522,0.053493689%20L26.9896814,3.7802205%20C27.5861486,3.95882536%2027.9967414,4.51354916%2027.9999817,5.1451433%20L27.9999817,12.8130848%20C28.0115347,21.4806488%2022.5484452,29.1783965%2014.4487468,31.9073802%20C14.3049522,31.9651489%2014.1521959,31.9965095%2013.9975996,32%20L13.9975996,32%20Z%20M16.8388676,19.8887472%20L16.8556656,19.9228703%20C16.8648162,19.942554%2016.8769638,19.96065%2016.8916614,19.9764923%20L19.051409,22.1701182%20C19.2455913,22.3586546%2019.5027242,22.4657329%2019.7713249,22.4699138%20C20.0402686,22.4674461%2020.2979983,22.3601193%2020.4912408,22.1701182%20C20.683558,21.9769865%2020.7916073,21.7136005%2020.7912515,21.4389096%20C20.7938073,21.1637783%2020.685415,20.8995563%2020.4912408,20.707701%20L18.3314931,18.514075%20C18.3180899,18.5021799%2018.3036297,18.4915726%2018.2882982,18.4823893%20C18.2717556,18.4739764%2018.2564167,18.4633167%2018.2427035,18.4507035%20C19.9963043,16.0045997%2019.7303004,12.6248051%2017.6163767,10.492716%20C16.4732537,9.32584755%2014.9175413,8.67273303%2013.2968815,8.67926919%20C11.6762217,8.67273302%2010.1205092,9.32584754%208.9773862,10.492716%20C6.60622074,12.9103716%206.60622074,16.8203159%208.9773862,19.2379715%20C10.1121465,20.3990541%2011.657352,21.0503558%2013.2680848,21.0464943%20C14.542857,21.0479015%2015.7856208,20.6410791%2016.8196698,19.8838725%20L16.8388676,19.8887472%20Z%20M13.3040806,18.9991314%20C12.2219104,19.0026627%2011.183935,18.5633888%2010.4244171,17.7804289%20C8.83956933,16.1684653%208.83956933,13.5573474%2010.4244171,11.9453839%20C11.1873326,11.1696138%2012.2245591,10.7368022%2013.3040806,10.7437643%20C14.3797116,10.7387033%2015.4125177,11.1714735%2016.1717455,11.9453839%20C16.9421551,12.7171299%2017.3745608,13.7711823%2017.3716204,14.8702185%20C17.3740201,15.9691455%2016.9416981,17.022994%2016.1717455,17.7950531%20C15.4133473,18.5690245%2014.3815746,19.0026015%2013.3064803,18.9991314%20L13.3040806,18.9991314%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
体内外疗效评估
建立多种稳定的细胞株，并优化了一系列细胞体外生物测定。针对每个靶点的作用机制开发了初始免疫细胞测定。此外，就疗效、药效动力学、作用机制及转化研究建立各种人源化小鼠模型，以及进行初步毒理学及药代动力学分析
'%20fill='%23A98C60'%20fill-rule='nonzero'%3e%3cg%20id='icon_03备份'%20transform='translate(24,%201675)'%3e%3cpath%20d='M4.46579636,6.25629731%20C4.08088572,6.25629731%203.7903786,6.18463716%203.59792328,6.04495016%20C3.40362768,5.90526316%203.26825355,5.736964%203.18443976,5.54177202%20C3.07395795,5.31800031%203.01871704,5.06551914%203.01871704,4.78617758%20L3.01871704,2.01618367%20C3.01871704,1.48264161%203.1220637,1.08512081%203.32878932,0.818301123%20C3.53545037,0.553298075%203.76358143,0.35096927%204.01130994,0.209498063%20C4.31427936,0.0698435012%204.64394909,0%205.00390285,0%20L20.9994872,0%20C21.3576975,0%2021.6873995,0.0698435012%2021.9920801,0.209498063%20C22.2397763,0.35093683%2022.4678751,0.553298075%2022.6746007,0.818301123%20C22.8813586,1.08512081%2022.984673,1.48264161%2022.984673,2.01618367%20L22.984673,4.78621002%20C22.984673,5.06555158%2022.9275918,5.31803275%2022.8171745,5.54180446%20C22.7351687,5.73699644%2022.6051218,5.9052956%2022.4250965,6.0449826%20C22.2468469,6.1846696%2021.9653475,6.25629731%2021.5786288,6.25629731%20L4.46579636,6.25629731%20Z%20M26,29.682158%20C26,30.2980978%2025.8912939,30.8585976%2025.6703303,31.3616784%20C25.477875,31.7824588%2025.180265,32.1585042%2024.781084,32.4951025%20C24.3819031,32.8317008%2023.81164,33%2023.0667433,33%20L2.97777872,33%20C2.20614944,33%201.6269432,32.8317008%201.24028913,32.4951025%20C0.855378494,32.1584393%200.56671166,31.7823939%200.374224056,31.3616784%20C0.153260426,30.8585327%200.0285083117,30.2980978%200,29.682158%20L0,13.9807031%20C0,13.0568095%200.167498438,12.3996382%200.497200453,12.0075349%20C0.826870183,11.6153992%201.13155075,11.2805851%201.40781986,10.9994593%20L4.34104425,8.22943299%20L22.2398731,8.22943299%20L24.5957316,10.9994593%20C24.8701927,11.2805851%2025.1749055,11.6153992%2025.5046075,12.0075349%20C25.836053,12.3996382%2026,13.0568095%2026,13.9807031%20L26,29.682158%20Z%20M19.5525047,18.8510302%20L15.2133007,18.8510302%20L15.2133007,14.3997316%20L10.790283,14.3997316%20L10.790283,18.8510302%20L6.44920645,18.8510302%20L6.44920645,23.3418408%20L10.790283,23.3418408%20L10.790283,27.7501887%20L15.2133007,27.7501887%20L15.2133007,23.3417759%20L19.5525047,23.3417759%20L19.5525047,18.8510302%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
成药性评估
综合运用软件分析、理化测试、免疫测定、加速测试及药代动力研究方法进行全面的成药性评估。通过评估候选分子的多个参数，识别并筛选出符合严格成药性要求的先导分子
临床开发
高效地设计及实施临床试验，通过出色的临床结果证明创新药物的优势
170家以上
合作的临床试验基地
2.3年
从首次人体试验的首名患者入组推进到关键性临床试验阶段
* 根据弗若斯特沙利文的资料，显著快于行业6.4年的平均水平
'%20fill='%23A98C60'%20fill-rule='nonzero'%3e%3cg%20id='icon_04备份'%20transform='translate(20,%202615)'%3e%3cpath%20d='M16,32%20L0,24.8192948%20L0,19.5276929%20L16,26.7083669%20L32,19.5276929%20L32,24.8192948%20L16,32%20Z%20M0,16%20L0,10.7083981%20L16,17.8891033%20L32,10.7083981%20L32,16%20L16,23.1807052%20L0,15.9999687%20L0,16%20Z%20M0,7.18070519%20L16,0%20L32,7.18070519%20L16,14.3613791%20L0,7.18067394%20L0,7.18070519%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
策略性及适应性的临床策略
根据项目特点设计产品研发和注册策略，实现中国和全球区域差异化布局和有效的临床开发
'%20fill='%23A98C60'%20fill-rule='nonzero'%3e%3cg%20id='icon_05备份'%20transform='translate(20,%202795)'%3e%3cpath%20d='M20.2993647,0.0045260568%20C21.4173008,0.606491611%2021.8518022,1.51622903%2021.7703332,2.80162916%20C21.6888642,4.04629478%2021.7477029,5.28643434%2021.7477029,6.53109996%20C21.7477029,8.41393959%2021.0416381,9.12000445%2019.0954336,9.12000445%20L15.1577642,9.12000445%20C13.709426,9.14263473%2012.6322245,10.2198363%2012.6095942,11.6455441%20L12.6095942,19.3081583%20C12.6095942,21.0054296%2011.8446906,21.752229%2010.1428933,21.752229%20L2.40333616,21.752229%20C0.787533883,21.752229%200,20.9646951%200,19.3307886%20L0,11.47808%20C0,9.92564256%200.80563811,9.11547839%202.36260165,9.11547839%20C4.84740683,9.09284811%207.33221201,9.11547839%209.82154325,9.11547839%20C11.5821793,9.11547839%2012.6367506,8.06090716%2012.6367506,6.31837529%20C12.6367506,5.13707447%2012.7001154,3.97840393%2012.6141203,2.7971031%20C12.510021,1.51170297%2012.9671527,0.601965554%2014.0850888,0%20L20.2993647,0%20L20.2993647,0.0045260568%20Z'%20id='路径'%3e%3c/path%3e%3cpath%20d='M22.1233656,10.9847398%20C23.4721306,10.9847398%2024.8163694,10.9621096%2026.1606083,10.9847398%20C27.5274774,11.0073701%2028.3557458,11.8130082%2028.3783761,13.1798774%20C28.4010064,15.9136157%2028.4010064,18.6292498%2028.3783761,21.3629881%20C28.3783761,22.793222%2027.5501077,23.5988601%2026.1198738,23.6214904%20C23.5943341,23.6441207%2021.0868986,23.6214904%2018.5613589,23.6214904%20C16.8007228,23.6214904%2015.7461516,24.6760617%2015.7461516,26.4366978%20C15.7461516,27.7809366%2015.7687819,29.1297016%2015.7461516,30.4739404%20C15.7235213,31.9041744%2014.9178832,32.7098125%2013.4876493,32.7324428%20C11.9352118,32.755073%2010.3827743,32.755073%208.82581076,32.7324428%20C7.4589416,32.7098125%206.64877744,31.9041744%206.63067321,30.5373052%20C6.60804293,28.9486593%206.60804293,27.3600133%206.63067321,25.7713674%20C6.65330349,24.4859673%207.49967611,23.6576989%208.78507625,23.6395947%20C10.2334144,23.6169644%2011.6862787,23.6395947%2013.1346168,23.6395947%20C14.6689501,23.6169644%2015.7235213,22.5623931%2015.7235213,21.0506902%20L15.7235213,13.4921753%20C15.7235213,11.7722737%2016.4884249,11.0073701%2018.167592,11.0073701%20C19.4892006,10.9847398%2020.8153352,10.9847398%2022.1233656,10.9847398%20Z'%20id='路径'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
快速推进临床开发
通过对未获满足的适应症快速进入市场，并通过广泛的适应症扩展最大化临床潜力
'%20fill='%23A98C60'%20fill-rule='nonzero'%3e%3cg%20id='icon_06备份'%20transform='translate(20,%202975)'%3e%3cpath%20d='M28.4864865,24.5292387%20L28.4864865,26.3048964%20C28.4864865,28.8212027%2026.3618694,30.8603604%2023.7387387,30.8603604%20L4.74774775,30.8603604%20C2.12461712,30.8603604%200,28.8212027%200,26.3048964%20L0,24.6336892%20L28.4864865,24.5292387%20L28.4864865,24.5292387%20Z%20M23.7387387,0%20C26.3618694,0%2028.4864865,2.10087838%2028.4864865,4.69077477%20L28.4864865,22.0485405%20L0,22.1553649%20L0,4.69077477%20C0,2.10087838%202.12461712,0%204.74774775,0%20L6.77028829,0%20L6.76316667,10.1554324%20L6.77266216,10.2812477%20C6.86761712,10.8391081%207.49669369,11.1192252%207.97384234,10.8177432%20L11.5583919,8.57680631%20L15.0266216,10.8129955%20C15.2688433,10.9698585%2015.5772962,10.9822646%2015.8313333,10.8453613%20C16.0853704,10.708458%2016.2446196,10.4440024%2016.2467928,10.1554324%20L16.2562883,0%20L23.7387387,0%20L23.7387387,0%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
监管路径管理
善于管理主要国家及地区复杂的监管路径，以加快药物注册的时间表。不断监测新的注册趋势并计划多中心试验，从而以最佳的人力及资源分配实现全球注册
CMC及生产
建立符合GMP标准的中试生产设施，并将制剂工艺开发、技术转移等无缝衔接，利用现代设施及先进技术，大大缩短生产周期，同时确保遵守最严格的质量标准
6月内
完成GMP合规批量原液生产
12月内
备妥CMC相关IND申报资料
'%20fill='%23A98C60'%20fill-rule='nonzero'%3e%3cg%20id='icon_07备份'%20transform='translate(20,%203695)'%3e%3cpath%20d='M30.0404386,0%20L2.01219298,0%20C0.904920107,0.00967105713%200.00967105713,0.904920107%200,2.01219298%20L0,19.3562281%20C0.00967105713,20.4635009%200.904920107,21.35875%202.01219298,21.3684211%20L30.0404386,21.3684211%20C31.1477115,21.35875%2032.0429605,20.4635009%2032.0526316,19.3562281%20L32.0526316,2.01219298%20C32.0429605,0.904920107%2031.1477115,0.00967105713%2030.0404386,0%20L30.0404386,0%20Z%20M14.245614,7.12280702%20L10.6842105,10.6842105%20L14.245614,14.245614%20L14.245614,17.8070175%20L7.12280702,10.6842105%20L14.245614,3.56140351%20L14.245614,7.12280702%20Z%20M17.8070175,17.8070175%20L17.8070175,14.245614%20L21.3684211,10.6842105%20L17.8070175,7.12280702%20L17.8070175,3.56140351%20L24.9298246,10.6842105%20L17.8070175,17.8070175%20Z%20M27.2269298,24.9298246%20L19.5877193,24.9298246%20L19.5877193,23.1491228%20L12.4649123,23.1491228%20L12.4649123,24.9298246%20L4.82570175,24.9298246%20C4.49038901,24.9298246%204.16880981,25.063027%203.93170789,25.3001289%20C3.69460598,25.5372309%203.56140351,25.8588101%203.56140351,26.1941228%20L3.56140351,27.2269298%20C3.56140351,27.9251825%204.12744911,28.4912281%204.82570175,28.4912281%20L27.2269298,28.4912281%20C27.9251825,28.4912281%2028.4912281,27.9251825%2028.4912281,27.2269298%20L28.4912281,26.1941228%20C28.4912281,25.4958702%2027.9251825,24.9298246%2027.2269298,24.9298246%20L27.2269298,24.9298246%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
高效的抗体开发平台
已建立完整高效的抗体药开发平台，包括工艺开发、分析方法开发、质量控制以及中试原液生产
'%20fill='%23A98C60'%20fill-rule='nonzero'%3e%3cg%20id='icon_08备份'%20transform='translate(24,%203869)'%3e%3cpath%20d='M17.7058824,16.4117647%20C17.7058824,17.9117647%2017,19.2352941%2015.9117647,20.0882353%20L14.3235294,18.5%20L12.6470588,20.1764706%20L13.5588235,21.0882353%20C13.3823529,21.1176471%2013.1764706,21.1176471%2013,21.1176471%20C10.4117647,21.1176471%208.29411765,19%208.29411765,16.4117647%20C8.29411765,13.8235294%2010.4117647,11.7058824%2013,11.7058824%20C15.5882353,11.7058824%2017.7058824,13.8235294%2017.7058824,16.4117647%20L17.7058824,16.4117647%20Z%20M26.0294118,6%20L26.0294118,15%20C26.0294118,23.3235294%2020.4705882,31.0882353%2013.0294118,33%20C5.55882353,31.1176471%200,23.3235294%200,15%20L0,6%20L13.0294118,0%20L26.0294118,6%20Z%20M17.5882353,21.7647059%20C19.0882353,20.4705882%2020.0588235,18.5588235%2020.0588235,16.4117647%20C20.0588235,12.5%2016.9117647,9.35294118%2013,9.35294118%20C9.08823529,9.35294118%205.94117647,12.5294118%205.94117647,16.4117647%20C5.94117647,20.2941176%209.08823529,23.4705882%2013,23.4705882%20C13.8823529,23.4705882%2014.7058824,23.2941176%2015.5,23.0294118%20L17.6470588,25.1764706%20L19.3235294,23.5%20L17.5882353,21.7647059%20L17.5882353,21.7647059%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
全生命周期质量管理体系
已建立覆盖药物发现、开发、生产和交付的全生命周期质量管理体系，符合中国国家药品监督管理局和美国食品药品监督管理局的所有适用标准和法规
'%20fill='%23A98C60'%20fill-rule='nonzero'%3e%3cg%20id='icon_09备份'%20transform='translate(24,%204081)'%3e%3cpath%20d='M28.1618497,5.28034682%20L14.6676301,10.8959537%20L1.1734104,5.28034682%20L14.6676301,0%20L28.1618497,5.28034682%20M0.0838150453,7.62716762%20L13.4942197,13.3265896%20L13.4942197,28.8323699%20C12.4046243,28.3294797%2011.3150289,27.8265896%2010.1416185,27.3236994%20C9.05202312,26.8208092%207.87861272,26.3179191%206.78901734,25.8150289%20C5.5317919,25.2283237%204.27456648,24.7254335%203.01734104,24.1387283%20C2.5982659,23.8872832%202.17919076,23.6358381%201.7601156,23.300578%20C1.42485547,22.9653179%201.08959535,22.5462428%200.838150305,22.1271676%20C0.586705228,21.7080925%200.335260122,21.2890173%200.251445077,20.7861272%20C0.0838150158,20.367052%200,19.8641618%200,19.4450867%20L0.0838150453,7.62716762%20M29,7.62716762%20L29,19.5289017%20C29,20.1156069%2028.916185,20.6184971%2028.6647399,21.1213873%20C28.4971098,21.6242775%2028.1618497,22.1271676%2027.9104046,22.5462428%20C27.5751445,22.9653179%2027.2398844,23.384393%2026.8208092,23.7196532%20C26.4017341,24.0549133%2026.066474,24.3063583%2025.6473988,24.5578035%20C24.5578035,25.0606936%2023.3843931,25.4797688%2022.2109827,25.9826589%20C21.0375723,26.4855491%2019.9479769,26.9884393%2018.9421965,27.4075144%20C17.7687861,27.9104046%2016.6791908,28.4132948%2015.5057803,28.8323699%20L15.5057803,13.3265896%20L29,7.62716762%20L29,7.62716762%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
生产设施和能力
符合GMP和cGMP的中试原液生产平台，配备200L/500L规模的一次性生物反应器生产线，可灵活调整生产规模，以支持候选药物的早期临床开发
'%20fill='%23868686'%20fill-rule='nonzero'%3e%3cg%20id='icon_qx'%20transform='translate(343,%20613)'%3e%3cpath%20d='M14.7073469,13.2954501%20L8.91225312,7.50026721%20L14.7073246,1.70450489%20C14.8962609,1.51559088%2015.0001781,1.26441124%2015,0.997208354%20C14.9998215,0.730807741%2014.8960603,0.480742374%2014.7078594,0.293076342%20C14.5193688,0.104095468%2014.2690361,0.000155995232%2014.0025909,0%20C13.7350091,0%2013.4840969,0.103917194%2013.2953612,0.292586056%20L7.50042344,6.0875461%20L1.70450512,0.292586078%20C1.51583626,0.103917216%201.26512461,0%200.998545704,0%20C0.731989095,0%200.481277447,0.103894915%200.292630864,0.292541498%20C0.104028861,0.480630937%200.000178524818,0.730807741%200,0.997208354%20C-0.000178045047,1.26441124%200.103739127,1.51559088%200.292630864,1.70448261%20L6.0885046,7.50024494%20L0.292608586,13.2954724%20C0.103917423,13.4841413%200,13.7348083%200,14.0014095%20C0,14.2679661%200.103939724,14.5187%200.292630886,14.7073912%20C0.481277469,14.8960601%200.731966816,14.9999327%200.998523446,14.9999327%20C1.26510236,14.9999327%201.51583628,14.8960378%201.70448287,14.7073912%20L7.50033432,8.91227517%20L13.2954726,14.7073912%20C13.4841415,14.8960601%2013.735076,14.9999327%2014.0020115,14.9999327%20C14.2691252,14.9997544%2014.5192129,14.8960155%2014.7069458,14.7078369%20C15.0964959,14.3182422%2015.0966073,13.6847106%2014.7073469,13.2954501%20Z'%20id='路径'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)